Pharma BD Deal Intelligence
Roche's $8.3B acquisition of InterMune gave it pirfenidone (Esbriet) and command of the pulmonary fibrosis market, though the deal's follow-through has been middling—outcome tracking puts it as a solid-not-spectacular bet rather than a franchise-defining win.
Roche acquired InterMune for $8.3B for pulmonary fibrosis and respiratory therapeutics.
Roche to acquire InterMune for $8.3 billion to broaden and strengthen its respiratory portfolio, gaining access to pirfenidone (Esbriet) for idiopathic…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Roche acquired InterMune for $8.3B for pulmonary fibrosis and respiratory therapeutics.
The broader fibrotic disease pipeline spans multiple MOAs addressing pulmonary, hepatic, renal, and dermal fibrosis, with Esbriet (pirfenidone) facing direct and indirect threats beyond IPF. Anti-fibrotic small molecules: nintedanib (Ofev, Boehringer Ingelheim) is approved for IPF, systemic-sclerosis-associated ILD, and progressive fibrosing ILD, generating ~EUR3.2B in 2023; pirfenidone (Esbriet, Roche) has lost exclusivity and faces generics erosion. Dual CTGF/TGF-beta pathway modulators: pamrevlumab (anti-CTGF, FibroGen) failed Phase 3 in IPF (ZEPHYRUS-1, 2023); BI 1015550 (BI/Boehringer, PDE4B inhibitor) is in Phase 3 FIBRONEER for IPF and progressive pulmonary fibrosis. Autotaxin-LPA axis: ziritaxestat (Galapagos) failed Phase 3 (ISABELA, 2021). NASH/MASH fibrosis: resmetirom (Rezdiffra, Madrigal) received FDA approval March 2024 as the first MASH therapy with fibrosis improvement. IL-11 antagonists and integrin inhibitors (e.g., bexotegrast, Pliant) are in earlier development for IPF and PSC. For Roche, pirfenidone's lifecycle has been constrained by nintedanib's broader label and the absence of a successful next-generation anti-fibrotic; pipeline expansion requires new MOAs rather than pirfenidone line extensions.
IPF is a two-drug market facing pipeline disruption. Anti-fibrotic small molecules dominate: pirfenidone (Esbriet, Roche; approved 2014) and nintedanib (Ofev, Boehringer Ingelheim; approved 2014) are the only FDA-approved therapies, with Ofev generating ~EUR3.2B in 2023 across IPF and broader ILD indications. Esbriet lost US patent protection in 2022 and faces multi-source generic competition. Next-generation MOAs advancing in Phase 3: nerandomilast (BI 1015550, Boehringer, PDE4B inhibitor) showed positive Phase 2 data and is in FIBRONEER-IPF; pamrevlumab (anti-CTGF mAb, FibroGen) failed ZEPHYRUS-1 in 2023, removing a key threat. Autotaxin-LPA antagonists (ziritaxestat, Galapagos) failed Phase 3 ISABELA. Earlier-stage: bexotegrast (PLN-74809, Pliant, integrin alphavbeta6 inhibitor) Phase 2b; BMS-986278 (BMS, LPA1 antagonist) Phase 3. Adjacent MOAs include PRM-151 (pentraxin-2, Roche/Promedior, discontinued 2023). Supportive care with pulmonary rehabilitation, oxygen, and lung transplant remains standard. For Roche, Esbriet's commercial window has effectively closed; the IPF franchise value now sits with Boehringer's Ofev plus emerging PDE4B class, with limited durable threat from Roche's own pipeline extensions.
Roche acquired InterMune at $74/share to gain Esbriet (pirfenidone) for idiopathic pulmonary fibrosis.
Esbriet approved for idiopathic pulmonary fibrosis, establishing Roche in fibrosis market.
Peak annual sales of $1.2B but consistently trailed competitor Ofev by nearly 3x.
Sandoz launched generic pirfenidone, rapidly eroding Esbriet revenue. Part of Roche Holding AG's $8.3B deal to acquire InterMune Inc..
After a decade, Roche divested US Esbriet rights, effectively exiting the IPF market.
Underperformed vs. Competitor. Assessment of Roche Holding AG's $8.3B acquisition of InterMune Inc. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / InterMune Inc. (this deal) | 2014 | $8.3B | 54 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2014 deals · Roche Holding AG deals · Respiratory deals